News

The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…

A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…

The American Liver Foundation (ALF) has launched a toolkit — featuring a plush lion named Bili the Brave — to support children and families…

Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…

U.K. regulators have approved Iqirvo (elafibranor) for adults with primary biliary cholangitis (PBC) who fail to respond to or cannot tolerate first-line…

Women who conceive with the help of in vitro fertilization (IVF) — a commonly used assisted reproductive technology — are almost three times more likely…

The U.S. Food and Drug Administration (FDA) has given breakthrough therapy designation to denifanstat, Sagimet Biosciences’ investigational oral therapy for metabolic dysfunction-associated steatohepatitis…

Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome,…

October is National Liver Awareness Month, and the American Liver Foundation (ALF) is promoting a series of activities and events to call attention to…